This observational cohort study evaluated the clinical safety of combining immune checkpoint inhibitors (ICIs) with Viscum album L. (mistletoe) extract in patients with advanced or metastatic cancer. Sixteen patients were included, with nine receiving both ICI and mistletoe therapy. The study found no statistically significant increase in adverse events (67%
